-
-
-
-
-
-
-
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

